<DOC>
	<DOCNO>NCT00333086</DOCNO>
	<brief_summary>Currently available treatment endometrial cancer associate limited efficacy significant toxicity . This study ass safety efficacy letrozole , aromatase inhibitor , endometrial cancer .</brief_summary>
	<brief_title>A Study Letrozole Treatment Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inclusion criterion Postmenopausal woman recurrent metastatic adeno adenosquamous carcinoma endometrium No adjuvant therapy Up one prior hormonal ( progestin ) therapy advanced/metastatic disease allow No chemotherapy recurrence ( adjuvant permit ) Unidimensionally measurable disease Good Health status 02 ( Eastern Cooperatitve Oncology Group ) No prior tamoxifen aromatase inhibitor therapy No concurrent anticancer treatment No metastases central nervous system Exclusion criterion : Additional protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Endometrial Cancer</keyword>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Letrozole</keyword>
</DOC>